{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:26:16Z","timestamp":1793647576688,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,8]],"date-time":"2007-02-08T00:00:00Z","timestamp":1170892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,8]],"date-time":"2007-02-08T00:00:00Z","timestamp":1170892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/sj.leu.2404586","type":"journal-article","created":{"date-parts":[[2007,2,8]],"date-time":"2007-02-08T07:24:01Z","timestamp":1170919441000},"page":"604-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":653,"title":["Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data"],"prefix":"10.1038","volume":"21","author":[{"given":"V H J","family":"van der Velden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Schrauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E R","family":"Panzer-Grumayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Flohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Cave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H O","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Trka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Foroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"zur Stadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Beldjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Raff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C E","family":"van der Schoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J M","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Study Group on MRD detection in ALL (ESG-MRD-ALL)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,8]]},"reference":[{"key":"BF2404586_CR1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","volume":"352","author":"JJM van Dongen","year":"1998","unstructured":"van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731\u20131738.","journal-title":"Lancet"},{"key":"BF2404586_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1056\/NEJM199808273390904","volume":"339","author":"H Cave","year":"1998","unstructured":"Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer \u2013 Childhood Leukemia Cooperative Group.. N Engl J Med 1998; 339: 591\u2013598.","journal-title":"N Engl J Med"},{"key":"BF2404586_CR3","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","volume":"96","author":"E Coustan-Smith","year":"2000","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691\u20132696.","journal-title":"Blood"},{"key":"BF2404586_CR4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V95.3.790.003k48_790_794","volume":"95","author":"ER Panzer-Grumayer","year":"2000","unstructured":"Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H . Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95: 790\u2013794.","journal-title":"Blood"},{"key":"BF2404586_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0140-6736(01)06355-3","volume":"358","author":"C Eckert","year":"2001","unstructured":"Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358: 1239\u20131241.","journal-title":"Lancet"},{"key":"BF2404586_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1182\/blood.V99.4.1253","volume":"99","author":"C Nyvold","year":"2002","unstructured":"Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253\u20131258.","journal-title":"Blood"},{"key":"BF2404586_CR7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","volume":"16","author":"P Bader","year":"2002","unstructured":"Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16: 1668\u20131672.","journal-title":"Leukemia"},{"key":"BF2404586_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","volume":"20","author":"FY Mortuza","year":"2002","unstructured":"Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 1094\u20131104.","journal-title":"J Clin Oncol"},{"key":"BF2404586_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.bmt.1704241","volume":"32","author":"O Krejci","year":"2003","unstructured":"Krejci O, van der Velden VH, Bader P, Kreyenberg H, Goulden N, Hancock J et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32: 849\u2013851.","journal-title":"Bone Marrow Transplant"},{"key":"BF2404586_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1046\/j.1365-2141.2003.04394.x","volume":"122","author":"N Goulden","year":"2003","unstructured":"Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24\u201329.","journal-title":"Br J Haematol"},{"key":"BF2404586_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.2003.10.080","volume":"21","author":"GM Marshall","year":"2003","unstructured":"Marshall GM, Haber M, Kwan E, Zhu L, Ferrara D, Xue C et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 704\u2013709.","journal-title":"J Clin Oncol"},{"key":"BF2404586_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Bruggemann","year":"2006","unstructured":"Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116\u20131123.","journal-title":"Blood"},{"key":"BF2404586_CR13","first-page":"127","volume":"3","author":"M Schrappe","year":"2002","unstructured":"Schrappe M . Risk-adapted therapy: lessons from childhood acute lymphoblastic leukemia. Hematol J 2002; 3: 127\u2013132.","journal-title":"Hematol J"},{"key":"BF2404586_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/sj.leu.2401780","volume":"14","author":"CH Pui","year":"2000","unstructured":"Pui CH, Campana D . New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 783\u2013785.","journal-title":"Leukemia"},{"key":"BF2404586_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VHJ van der Velden","year":"2003","unstructured":"van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013\u20131034.","journal-title":"Leukemia"},{"key":"BF2404586_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.leu.2401277","volume":"13","author":"T Szczepanski","year":"1999","unstructured":"Szczepanski T, Beishuizen A, Pongers-Willemse MJ, Hahlen K, Van Wering ER, Wijkhuijs AJ et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia 1999; 13: 196\u2013205.","journal-title":"Leukemia"},{"key":"BF2404586_CR17","doi-asserted-by":"crossref","unstructured":"van der Velden VHJ, Panzer-Gr\u00fcmayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2006, (in press).","DOI":"10.1038\/sj.leu.2404535"},{"key":"BF2404586_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/sj.leu.2402475","volume":"16","author":"VHJ van der Velden","year":"2002","unstructured":"van der Velden VHJ, Willemse MJ, van der Schoot CE, Hahlen K, van Wering ER, van Dongen JJM . Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928\u2013936.","journal-title":"Leukemia"},{"key":"BF2404586_CR19","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/sj.leu.2401801","volume":"14","author":"OJ Verhagen","year":"2000","unstructured":"Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426\u20131435.","journal-title":"Leukemia"},{"key":"BF2404586_CR20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/sj.leu.2402515","volume":"16","author":"VHJ van der Velden","year":"2002","unstructured":"van der Velden VHJ, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJM . T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 1372\u20131380.","journal-title":"Leukemia"},{"key":"BF2404586_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/sj.leu.2402184","volume":"15","author":"ER van Wering","year":"2001","unstructured":"van Wering ER, van der Linden-Schrever BE, van der Velden VHJ, Szczepanski T, van Dongen JJM . T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies. Leukemia 2001; 15: 1301\u20131303.","journal-title":"Leukemia"},{"key":"BF2404586_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/sj.leu.2401749","volume":"14","author":"EG van Lochem","year":"2000","unstructured":"van Lochem EG, Wiegers YM, van den Beemd R, Hahlen K, van Dongen JJM, Hooijkaas H . Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia 2000; 14: 688\u2013695.","journal-title":"Leukemia"},{"key":"BF2404586_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1046\/j.1365-2141.2000.02143.x","volume":"110","author":"ER van Wering","year":"2000","unstructured":"van Wering ER, van der Linden-Schrever BE, Szczepanski T, Willemse MJ, Baars EA, van Wijngaarde-Schmitz HM et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol 2000; 110: 139\u2013146.","journal-title":"Br J Haematol"},{"key":"BF2404586_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/sj.leu.2402751","volume":"17","author":"J Moppett","year":"2003","unstructured":"Moppett J, van der Velden VH, Wijkhuijs AJ, Hancock J, van Dongen JJ, Goulden N . Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin. Leukemia 2003; 17: 268\u2013270.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404586","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:39:04Z","timestamp":1648766344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["BF2404586"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404586","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,8]]},"assertion":[{"value":"23 November 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}